Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review

We present the case of PCNSL which developed in a patient with the active phase of neuropsychiatric SLE (NPSLE). Furthermore, we reviewed published English articles to confirm the chara cteristics of PCNSL related to SLE. To our knowledge, this is the first report of PCNSL occurring in NPSLE. Histology demonstrated B-cell lymphoma with a positive Epstein–Barr virus-encoded RNA. This patient recovered following surgical resection of the lymphoma, whole brain radiation therapy, int ravenous infusion of rituximab (RTX), and administration of belimumab after RTX. Given the series of reviews, our report suggests that the persistence of damage in the central nervous system (CNS) and long-term exposure to immunosuppressants may impact oncogenic immune responses within the CNS, lead ing to PCNSL development.
Source: Rheumatology International - Category: Rheumatology Source Type: research

Related Links:

Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. Bile acids are cholesterol metabolites that can signal through receptors on cells throughout the body, including in the CNS and the immune system. Whether bile acid metabolism is abnormal in MS is unknown. Using global and targeted metabolomic profiling, we identified lower levels of circulating bile acid metabolites in multiple cohorts of adult and pediatric patients with MS compared with controls. In white matter lesions from MS brain tissue, we noted the presence of bile acid receptors on immune and glial cells. To mechanistically examine the ...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Source: Clinical Epidemiology - Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
Publication date: Available online 26 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Zoe Bezirgiannidou, Aikaterini Pentidou, Georgios Vrachiolias, Ioannis Seimenis, Ioannis Kotsianidis, Emmanouil Spanoudakis
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aneri Patel, Bret C. Mobley, Madan Jagasia, Kassim Adetola, Michael Byrne, Bhagirathbhai Dholaria
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Singh BB, Ohm J, Quenum Zanbede FO, Chauhan P, Kroese FGM, Vissink A, Ambrus JL, Mishra BB Abstract Primary Sjogren's syndrome (pSS) is a systemic autoimmune disease that is characterized by the infiltration of immune cells. Although the loss of salivary gland function is a major manifestation observed in pSS, the factors that could promote these changes in salivary gland tissue in pSS is not yet determined. Herein, we provide evidence that loss of alpha-1 antiproteinase antitrypsin could contribute to the induction of pSS. Alpha-1 antiproteinase antitrypsin belongs to the family of serpin proteins that fu...
Source: Autoimmunity - Category: Allergy & Immunology Tags: Autoimmunity Source Type: research
Abstract Osteosarcoma is the most frequent and intractable malignancy of the bone in children and young adults. Surgical operation requires extensive excision of the cancer tissue and neighboring normal tissues. In addition, anticancer drugs and radiation therapy are thought to be almost ineffective. Glucose-regulated protein 78 (GRP78), a cell-protective endoplasmic reticulum (ER) chaperone protein, is one of the most promising anticancer targets for osteosarcoma. Here, by analyzing the molecular mechanisms of kuanoniamine C, we report that kuanoniamine C suppresses GRP78 expression via GRP78 mRNA degradation in ...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Abstract Blocking of the interaction between Programmed cell death 1 (PD-1) and its ligand PD-L1 by monoclonal antibodies has elicited unprecedented therapeutic benefits and achieved a major breakthrough in immunotherapy of multiple types of tumors. Here, we determined the crystal structure of PD-1 in complex with the Fab fragment of tislelizumab. This monoclonal antibody was approved in December 2019 by the China National Medical Product Administration for Hodgkin's lymphoma and is under multiple clinical trials in China and the US. While the three complementarity determining regions (CDRs) in the light chain are...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Since the start of the Covid-19 crisis, many hospitals have suspended routine cancer surgeries and chemotherapiesCoronavirus – latest updatesSee all our coronavirus coverageWhen I was diagnosed with stage four Hodgkin ’s lymphoma at the beginning of February, my mind immediately turned not to the illness and pain I knew would have to endure, but to the sadness of putting my life on pause. I could never have predicted that the world would end up putting its life on pause with me.My treatment – an intensive chemotherapy regimen – began on 4 March and finished on 12 May, coinciding closely with the UK ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cancer Coronavirus outbreak Society Infectious diseases Medical research Microbiology Science World news Health NHS Hospitals & wellbeing Life and style Students Universities Education Higher education Society Professio Source Type: news
The FDA granted fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom ’s macroglobulinemia in patients having received 2 prior treatment regimens or more.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
(NIH/National Cancer Institute) In a new study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Autoimmune Disease | Brain | Hodgkin's Disease | Lupus | Lymphoma | Neurology | Primary CNS Lymphoma | Radiation Therapy | Rheumatology | Rituxan | Study